Publications
Publications
Show Results For
- All HBS Web
(860)
- Faculty Publications (53)
- July 2018
- Case
Ce Soir-Là, Ils n'Arrivent Plus Un par Un, Mais par Vagues: Coping with the Surge of Trauma Patients at L'Hôpital Universitaire La Pitié Salpêtrière—Friday, November 13, 2015
By: Herman B. "Dutch" Leonard, Emilie Billaud and Arnold M. Howitt
On November 13, 2015, Dr. Marie Borel, Dr. Emmanuelle Dolla, Dr. Frédéric Le Saché, and Professor Mathieu Raux were the doctors in charge of the trauma center at L’Hôpital de la Pitié Salpêtrière in Paris, where dozens of wounded and dying patients, most with severe... View Details
- Article
(Mis)perceptions of Inequality
By: Oliver P. Hauser and Michael I. Norton
Inequality is arguably the defining societal issue of the 21st century. The debate over “who gets what’ underlies policy debates ranging from taxation to health care to wages and permeates society at all levels, attracting increasing interest from policymakers,... View Details
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details
- June 2017
- Case
MIA: Profit at the Base of the Pyramid
By: Lynda M. Applegate, José Antonio Dávila Castilla, Sarah Mehta and Aldo Sesia
In January 2016, Guillermo Jaime had just returned home to Mexico City after attending a Harvard Business School executive education program. Jaime was the founder and CEO of Mejoramiento Integral Asistido (MIA), a company providing affordable housing to low-income... View Details
- Article
Why Do Firms Have 'Purpose'? The Firm's Role as a Carrier of Identity and Reputation
By: Rebecca Henderson and Eric Van den Steen
Why do so many firms publicly espouse a "purpose" beyond simple profit maximization? And why do so many managers and employees appear to care deeply about this purpose and to believe that it is critically important? In this paper we argue that the conventional answers... View Details
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
- 2015
- Other Teaching and Training Material
Innovating in Healthcare
By: Regina E. Herzlinger, Margo I. Seltzer and Kevin Schulman
With over 71,000 past enrollees, Innovating in Healthcare investigates the issues of health care spending, quality, and access that continue to plague America and global nations alike. With U.S. health care costs trending toward $4 trillion in 2020, the need to... View Details
- Article
Teaming: An Approach to the Growing Complexities in Health Care: AOA Critical Issues
By: Haseeb Nawaz, Amy C. Edmondson, Tony H. Tzeng, Jamal K. Saleh, Kevin J. Bozic and Khaled J. Saleh
Confronted with rising costs and patients who often have multiple comorbidities, the orthopaedic surgeon needs to face the challenge of providing high-quality health care. One solution is to increase and improve coordination, communication, and teamwork. The... View Details
- March 2014 (Revised September 2014)
- Supplement
Cancer Treatment Centers of America® (B)
By: Regina E. Herzlinger and Natalie Kindred
This case, a follow-up to Cancer Treatment Centers of America (A), HBS No. 313-012, begins with the debate over New Hampshire's certificate-of-need (CON) law, which restricts hospital expansion. This debate ignited significant public criticism of Cancer Treatment... View Details
Keywords: Cancer; Cancer Treatment; Accountability; Outcomes; Outcomes Reporting; Outcomes Measurement; Survival; For-profit Hospitals; Health Care; Healthcare; Hospital; Certificate Of Need; Health Care and Treatment; Outcome or Result; Corporate Accountability; Policy; Health Industry; United States
- June 2013
- Case
Ron Ventura at Mitchell Memorial Hospital
By: Frank V. Cespedes and Heide Abelli
Mitchell Memorial Hospital is a 750-bed regional academic medical center in Ohio. Andy Prescott, Chief of the Cardiovascular Center, is reviewing the performance evaluations of his star vascular surgeon Ron Ventura. The evaluations, the result of a 360-degree... View Details
- May 2013
- Article
Health Care's Service Fanatics: How the Cleveland Clinic Leaped to the Top of the Patient-satisfaction Surveys
By: James Merlino and Ananth Raman
The Cleveland Clinic has long had a reputation for medical excellence. But in 2009 the CEO acknowledged that patients did not think much of their experience there, and he decided to act. Since then the Clinic has leaped to the top tier of patient-satisfaction surveys,... View Details
- 2012
- Working Paper
No News Is Good News: CSR Strategy and Newspaper Coverage of Negative Firm Events
By: Jiao Luo, Stephan Meier and Felix Oberholzer-Gee
One of the benefits of Corporate Social Responsibility (CSR) programs, it has been argued, is that they build up a reservoir of public good will, shielding companies in times of trouble. In this paper, we test the view that CSR provides protection from public ire by... View Details
- July 2011 (Revised September 2012)
- Case
Intraoperative Radiotherapy for Breast Cancer (A)
By: Willy Shih
"This trial is going to take longer." Those were words that Michael Kaschke, CEO of Carl Zeiss AG, was not surprised to hear as he nurtured the intraoperative radiotherapy business inside his company's microsurgery unit. But he also didn't expect it to take 13 years to... View Details
- September 2009 (Revised May 2011)
- Supplement
Acumen Fund: Measurement in Impact Investing (B)
By: Alnoor Ebrahim and V. Kasturi Rangan
As Acumen Fund, a global venture philanthropy firm, moves forward with an investment portfolio exceeding $22 million, it runs into two critical measurement problems. First, how should it track the performance of each investment when its interest is not just the bottom... View Details
- March 2009 (Revised September 2010)
- Case
Dartmouth-Hitchcock Medical Center: Spine Care
By: Robert S. Huckman, Michael E. Porter, Rachel Gordon and Natalie Kindred
Describes the Spine Center at Dartmouth-Hitchcock Medical Center, a multidisciplinary unit that offers patients suffering from spinal problems "one-stop" access to a range of providers including orthopedic surgeons, neurosurgeons, neurologists, medical specialists in... View Details
- July 2008 (Revised August 2008)
- Case
In-Vitro Fertilization: Outcomes Measurement
By: Michael E. Porter, Saquib Rahim and Benjamin Chung-Shi Tsai
As of 2007, there were very few examples of widespread measurement and reporting of health outcomes, a critical quality measure. In-vitro fertilization clinics have been required to report their patient's health outcomes since 1995. The protagonist of the case, Dr.... View Details
- June 2008
- Case
Gordon Williams: Clinical Research at Brigham and Women's Hospital
By: H. Kent Bowen and Courtney Purrington
Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train... View Details
- September 2006 (Revised December 2006)
- Case
Arizona Department of Public Health: The Challenges of Preparing for a Public Health Emergency
By: Lynda M. Applegate, Ajay Vinze, T. S. Raghu and Minu Ipe
In the post-9/11 era information technology enablement for emergency preparedness and response have taken on increased significance. Public health organizations like ADHS play a critical role in any statewide preparation for large scale emergencies. With issues like... View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details